Vor Biopharma (VOR) Non Operating Income (2020 - 2026)
Vor Biopharma (VOR) reported Non Operating Income of -$184.4 million for Q1 2026, down 23009.94% year-over-year from N/an in Q1 2025, and down 110.49% on a QoQ basis from $1.8 billion in Q4 2025.
Vor Biopharma (VOR) has 7 years of Non Operating Income data on file, last reported at -$184.4 million in Q1 2026.
- Quarterly Non Operating Income fell 23009.94% year-over-year to -$184.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$509.6 million (down 14437.9% YoY) and the FY2025 annual result came in at -$324.3 million, down 7693.98% from the prior year.
- Non Operating Income retreated to -$184.4 million in Q1 2026 per VOR's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Non Operating Income topped out at $1.8 billion in Q4 2025 and bottomed at -$1.3 billion in Q2 2025.
- The 5-year median for Non Operating Income is $815000.0 (2022), against an average of -$29.1 million.
- Peak annual rise in Non Operating Income reached 293525.71% in 2025, while the deepest fall reached 108744.23% in 2025.
- Tracing VOR's Non Operating Income over 5 years: stood at $815000.0 in 2022, then jumped by 128.59% to $1.9 million in 2023, then tumbled by 67.85% to $599000.0 in 2024, then jumped by 293525.71% to $1.8 billion in 2025, then slumped by 110.49% to -$184.4 million in 2026.
- Per Business Quant, the three latest VOR Non Operating Income figures stand at -$184.4 million (Q1 2026), $1.8 billion (Q4 2025), and -$784.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -184.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -184.43 Mn |
| Dec 31, 2025 | 1.76 Bn |
| Sep 30, 2025 | -784.58 Mn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 599,000.00 |
| Sep 30, 2024 | 954,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 1.99 Mn |
| Dec 31, 2022 | 815,000.00 |
| Sep 30, 2022 | 313,000.00 |
| Jun 30, 2022 | 133,000.00 |
| Mar 31, 2022 | 63,000.00 |
| Dec 31, 2021 | 54,000.00 |
| Sep 30, 2021 | 48,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Mar 31, 2020 | 29,000.00 |